Sugi Predict

Sugi Predict / Compounds / SCHEMBL7164348

SCHEMBL7164348

SCHEMBL7164348

Cc1cc(Oc2ccncc2)ccc1S(=O)(=O)Nc1c(C(=O)O)cnc2c1c(-c1ccccc1)nn2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 2/20 0.43
▸ MMP9 P14780 2/20 0.43
▸ MMP13 P45452 2/20 0.43
▸ NUDT14 O95848 1/20 0.38
▸ NUDT5 Q9UKK9 1/20 0.38
▸ BCL2L1 Q07817 3/20 0.38
▸ MCL1 Q07820 3/20 0.38
▸ SCN9A Q15858 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ ACLY P53396 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ CYP2C9 P11712 3/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ ADAM17 P78536 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014943 0.89 MMP1 (0.52) MMP1MMP9MMP13BCL2L1MCL1
SCHEMBL7164747 0.80 LMNA (0.52) MMP1MMP9MMP13ALDH1A1HPGD
SCHEMBL7161794 0.78 PDE4B (0.52) MMP1MMP9MMP13ADAM17PDE4A
SCHEMBL7160404 0.76 MMP1 (0.38) MMP1MMP9MMP13BCL2L1MCL1
SCHEMBL7160986 0.76 BRD4 (0.38) MMP1MMP9MMP13BCL2L1MCL1
SCHEMBL7005730 0.75 MMP9 (0.64) MMP1MMP9MMP13NUDT14NUDT5
SCHEMBL7016605 0.73 CYP1A2 (0.36) MMP1MMP9MMP13BCL2L1MCL1
Potassium Ion SCHEMBL7014935 0.70 MMP9 (0.62) MMP1MMP9MMP13NUDT14NUDT5
SCHEMBL7008512 0.70 MMP9 (0.61) MMP1MMP9MMP13ALDH1A1HSD17B10
SCHEMBL7014806 0.69 PDE4B (0.49) MMP1MMP9MMP13ADAM17PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548524-B2 Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors AMERICAN CYANAMID COMPANY 2003-04-15 — — US disclosed
US-20010046989-A1 Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors WYETH HOLDINGS CORPORATION 2001-11-29 — — US disclosed
EP-1021413-A1 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS American Cyanamid Company (US) 2000-07-26 — — EP disclosed
WO-1999018076-A1 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010046989-A1 Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors MSR1, TIMP3, TGFBR2 MMP1 51/4885MMP9 26/4885MMP13 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.